Allogene Therapeutics Announces CMO Departure, Board Changes
Ticker: ALLO · Form: 8-K · Filed: Jun 10, 2024 · CIK: 1737287
| Field | Detail |
|---|---|
| Company | Allogene Therapeutics, Inc. (ALLO) |
| Form Type | 8-K |
| Filed Date | Jun 10, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-departure, board-changes, stockholder-meeting
TL;DR
CMO out, new interim CMO in, board shuffled. Stockholder meeting held.
AI Summary
Allogene Therapeutics, Inc. announced on June 5, 2024, the departure of Chief Medical Officer, Dr. Anthony Davies, and the appointment of Dr. Jessica Ng as interim Chief Medical Officer. The company also reported on the election of new directors and changes to its board committees. Additionally, Allogene Therapeutics held its 2024 Annual Meeting of Stockholders on June 5, 2024, where proposals including the election of directors and an advisory vote on executive compensation were considered.
Why It Matters
Changes in key executive positions and board composition can signal shifts in company strategy or operational focus, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Executive departures and board changes can introduce uncertainty regarding leadership stability and strategic direction.
Key Players & Entities
- Allogene Therapeutics, Inc. (company) — Registrant
- Dr. Anthony Davies (person) — Departing Chief Medical Officer
- Dr. Jessica Ng (person) — Appointed interim Chief Medical Officer
- June 5, 2024 (date) — Date of earliest event reported
- 2024 Annual Meeting of Stockholders (event) — Meeting held on June 5, 2024
FAQ
Who has been appointed as the interim Chief Medical Officer?
Dr. Jessica Ng has been appointed as the interim Chief Medical Officer.
When was the earliest event reported in this filing?
The earliest event reported was on June 5, 2024.
What was the purpose of the meeting held on June 5, 2024?
The meeting held on June 5, 2024, was the 2024 Annual Meeting of Stockholders, where proposals including the election of directors and an advisory vote on executive compensation were considered.
Who departed from their role as Chief Medical Officer?
Dr. Anthony Davies departed from his role as Chief Medical Officer.
What is the principal executive office address of Allogene Therapeutics, Inc.?
The address of the principal executive offices is 210 East Grand Avenue, South San Francisco, California 94080.
Filing Stats: 872 words · 3 min read · ~3 pages · Grade level 10.8 · Accepted 2024-06-10 16:30:58
Key Financial Figures
- $0.001 — ge on which registered Common Stock, $0.001 par value per share ALLO The Nasdaq Sto
Filing Documents
- allo-20240605.htm (8-K) — 41KB
- 0001737287-24-000050.txt ( ) — 164KB
- allo-20240605.xsd (EX-101.SCH) — 2KB
- allo-20240605_lab.xml (EX-101.LAB) — 21KB
- allo-20240605_pre.xml (EX-101.PRE) — 12KB
- allo-20240605_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 5, 2024, Allogene Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 17, 2024, the record date for the Annual Meeting, 170,723,100 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. Proposal 1. Election of Directors The Company's stockholders elected the four persons listed below as Class III Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes John DeYoung 121,177,479 17,019,993 15,800,932 Franz Humer, Ph.D. 119,919,567 18,277,905 15,800,932 Joshua Kazam 127,917,055 10,280,417 15,800,932 Stephen Mayo, Ph.D. 130,166,905 8,030,567 15,800,932 Proposal 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement for the Annual Meeting. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 119,741,038 16,298,878 2,157,556 15,800,932 Proposal 3. Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 152,503,468 1,359,400 135,536 0
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibit Number Description 104 The cover page of this report has been formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALLOGENE THERAPEUTICS, INC. By: /s/ David Chang, M.D., Ph.D. David Chang, M.D., Ph.D. President, Chief Executive Officer Dated: June 10, 2024